Ausgabe 5/2014
Inhalt (25 Artikel)
Asparaginase in the treatment of non-ALL hematologic malignancies
Ashkan Emadi, Hania Zokaee, Edward A. Sausville
Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy
Aiwen Wu, Yongning Jia, Bin Dong, Lei Tang, Yiqiang Liu, Hong Du, Peng Yuan, Peide Dong, Jiafu Ji
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
Tadahiro Shoji, Eriko Takatori, Yoshitaka Kaido, Hideo Omi, Yoshihito Yokoyama, Hideki Mizunuma, Michiko Kaiho, Takeo Otsuki, Tadao Takano, Nobuo Yaegashi, Hiroshi Nishiyama, Keiya Fujimori, Toru Sugiyama
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer
S. Chan, M. Campone, A. Santoro, P. F. Conte, M. Bostnavaron, L. Nguyen
Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1)
Jan Hendrik Hooijberg, Gerrit Jansen, Ietje Kathmann, Rob Pieters, Adrie C. Laan, Ina van Zantwijk, Gertjan J. L. Kaspers, Godefridus J. Peters
Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy
Marta Simó, Andreas A. Argyriou, Miquel Macià, Gerard Plans, Carles Majós, Noemi Vidal, Miguel Gil, Jordi Bruna
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression
Massimo Maffezzini, Fabio Campodonico, Giorgio Canepa, Egi Edward Manuputty, Stefania Tamagno, Matteo Puntoni
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
Kelly K. Curtis, John Sarantopoulos, Donald W. Northfelt, Glen J. Weiss, Kerry M. Barnhart, John K. Whisnant, Carola Leuschner, Hector Alila, Mitesh J. Borad, Ramesh K. Ramanathan
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience
Yuka Kato, Katsuyuki Hotta, Nagio Takigawa, Naoyuki Nogami, Toshiyuki Kozuki, Akiko Sato, Eiki Ichihara, Kenichiro Kudo, Isao Oze, Masahiro Tabata, Tetsu Shinkai, Mitsune Tanimoto, Katsuyuki Kiura
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M. LoRusso, Wells A. Messersmith, Kyriakos P. Papadopoulos, Lia Gore, Muralidhar Beeram, Vanitha Ramakrishnan, Amy H. Kim, Joseph C. Beyer, L. Mason Shih, Walter C. Darbonne, Yan Xin, Ron Yu, Hong Xiang, Rainer K. Brachmann, Colin D. Weekes
Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102
John M. Fidler, Jinhua An, Bing Z. Carter, Michael Andreeff
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma
Oscar Arrieta, Diego López-Macías, Víctor-Osvaldo Mendoza-García, Ludwing Bacon-Fonseca, Wendy Muñoz-Montaño, Eleazar-Omar Macedo-Pérez, Saé Muñiz-Hernández, Monika Blake-Cerda, José-Francisco Corona-Cruz
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation
Xin Hong, James P. O’Donnell, Clarence R. Salazar, James R. Van Brocklyn, Kahlil D. Barnett, Dennis K. Pearl, Ana C. deCarvalho, Jeffrey A. Ecsedy, Stephen L. Brown, Tom Mikkelsen, Norman L. Lehman
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
Islam R. Younis, Daniel J. George, Terence J. McManus, Herbert Hurwitz, Patricia Creel, Andrew J. Armstrong, Jing Jie Yu, Kristina Bacon, Gerald Hobbs, Cody J. Peer, William P. Petros
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma
A. Thiery-Vuillemin, G. Mouillet, T. Nguyen Tan Hon, P. Montcuquet, T. Maurina, H. Almotlak, U. Stein, D. Montange, A. Foubert, V. Nerich, X. Pivot, B. Royer
Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients
Carlos Pérez-Ruixo, José E. Peris, Vanesa Escudero-Ortiz, Pedro Bretcha-Boix, José Farré-Alegre, Juan José Pérez-Ruixo, Belén Valenzuela
Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure
Suh-Young Lee, Hye-Ryun Kang, Woo-Jung Song, Kyung-Hun Lee, Sae-Won Han, Sang Heon Cho
No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
Nianhang. Chen, Daniel Weiss, Josephine Reyes, Liangang Liu, Claudia Kasserra, Xiaomin Wang, Simon Zhou, Gondi Kumar, Lilia Weiss, Maria Palmisano
Pharmacokinetics, placenta, and brain uptake of paclitaxel in pregnant rats
Na-Young Lee, Kyung-Bok Lee, Young-Sook Kang
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis
Toru Aoyama, Kazuhiro Nishikawa, Nobuhiro Takiguchi, Kazuaki Tanabe, Motohiro Imano, Ryoji Fukushima, Junichi Sakamoto, Mari S. Oba, Satoshi Morita, Toru Kono, Akira Tsuburaya
The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro
Michele Visentin, Ersin Selcuk Unal, I. David Goldman
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
Ji Yun Lee, Sung Hee Lim, Moonjin Kim, Sungmin Kim, Hyun Ae Jung, Won Jin Chang, Moon Ki Choi, Jung Yong Hong, Su Jin Lee, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
A phase I study of oral ixabepilone in patients with advanced solid tumors
John F. Deeken, John L. Marshall, Michael J. Pishvaian, Jimmy Hwang, Christoph M. Ahlers, Pamela L. Clemens, Susan M. Parker, Lisa Iacono, Patricia M. LoRusso
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer
Junichi Hasegawa, Junichi Nishimura, Tsunekazu Mizushima, Yasuhiro Miyake, Ho Min Kim, Hiroyoshi Takemoto, Hroshi Tamagawa, Shingo Noura, Makoto Fujii, Yujiro Fujie, Takeshi Kato, Hideaki Miwa, Ichiro Takemasa, Masataka Ikeda, Hirofumi Yamamoto, Mistugu Sekimoto, Riichiro Nezu, Yuichiro Doki, Masaki Mori
DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development
Eric D. Shah, Brandon M. A. Fisch, Robert J. Arceci, Jonathan D. Buckley, Gregory H. Reaman, Poul H. Sorensen, Timothy J. Triche, C. Patrick Reynolds